Evidence map›Paper›PMID 34334569›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Immunotherapy-responsive Non-paraneoplastic Encephalitis with Antibodies against GAD, LGI1, and GABA

Takahiro Nakano, Norio Chihara, Kento Matoba, Hisatsugu Tachibana, Shiho Okuda, Yoshihisa Otsuka, Takehiro Ueda, Kenji Sekiguchi, Hisatomo Kowa, Frank Leypoldt and 2 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Takahiro NakanoDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Norio ChiharaDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Kento MatobaDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Hisatsugu TachibanaDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Shiho OkudaDepartment of Neurology, Hyogo Rehabilitation Center Hospital, Japan.
Yoshihisa OtsukaDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Takehiro UedaDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Kenji SekiguchiDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Hisatomo KowaDepartment of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Japan.
Frank LeypoldtInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Germany.
Klaus-Peter WandingerInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Germany.
Riki MatsumotoDivision of Neurology, Kobe University Graduate School of Medicine, Japan.
Kobe University · JPHyogo Social Welfare Corporation · JPUniversity Hospital Schleswig-Holstein · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 62-year-old man showed abnormal behavior. Brain magnetic resonance imaging revealed multifocal lesions on T2-weighted images. Initial screening revealed that he was seropositive for antibodies against glutamate decarboxylase, which usually indicates treatment resistance to autoimmune encephalitis (AE). Intensive immunosuppressive therapies, however, improved the neurological symptoms. In line with this, we also detected seropositivity for antibodies against leucine-rich glioma-inactivated 1 and gamma-aminobutyric acid A receptor (GABA

Indexed as

EncephalitisHashimoto DiseaseLimbic EncephalitisAutoantibodiesHumansImmunotherapyIntracellular Signaling Peptides and ProteinsMaleMiddle AgedReceptors, GABA-AAutoantibodiesIntracellular Signaling Peptides and ProteinsLGI1 protein, humanReceptors, GABA-Aanti-GABAAR antibodyanti-GAD antibodyanti-LGI1 antibodyautoimmune encephalitisplasma exchange

Identifiers

PMID34334569
PMCPMC8866773
OpenAlexW3189202028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.